BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 21900222)

  • 1. Biosimilars: are they ready for primetime in the United States?
    Hirsch BR; Lyman GH
    J Natl Compr Canc Netw; 2011 Aug; 9(8):934-42; quiz 943. PubMed ID: 21900222
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biosimilars 101: considerations for U.S. oncologists in clinical practice.
    Camacho LH; Frost CP; Abella E; Morrow PK; Whittaker S
    Cancer Med; 2014 Aug; 3(4):889-99. PubMed ID: 24810680
    [TBL] [Abstract][Full Text] [Related]  

  • 3. NCCN Biosimilars White Paper: regulatory, scientific, and patient safety perspectives.
    Zelenetz AD; Ahmed I; Braud EL; Cross JD; Davenport-Ennis N; Dickinson BD; Goldberg SE; Gottlieb S; Johnson PE; Lyman GH; Markus R; Matulonis UA; Reinke D; Li EC; DeMartino J; Larsen JK; Hoffman JM
    J Natl Compr Canc Netw; 2011 Sep; 9 Suppl 4():S1-22. PubMed ID: 21976013
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biosimilars and the European experience: implications for the United States.
    Megerlin F; Lopert R; Taymor K; Trouvin JH
    Health Aff (Millwood); 2013 Oct; 32(10):1803-10. PubMed ID: 24101072
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development and regulation of biosimilars: current status and future challenges.
    Tsiftsoglou AS; Ruiz S; Schneider CK
    BioDrugs; 2013 Jun; 27(3):203-11. PubMed ID: 23553340
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biosimilars in the United States: Emerging Issues in Litigation.
    Wong AY; Rumore MM; Chan AW
    BioDrugs; 2017 Jun; 31(3):189-205. PubMed ID: 28424972
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Approval Process: An Overview of Biosimilars in the Oncology Setting.
    Sowinski-Raff L
    Clin J Oncol Nurs; 2018 Oct; 22(5):13-18. PubMed ID: 30239527
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biosimilars in oncology: from development to clinical practice.
    Rak Tkaczuk KH; Jacobs IA
    Semin Oncol; 2014 Apr; 41 Suppl 3():S3-S12. PubMed ID: 24767633
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biosimilars: Implications for Clinical Practice.
    Rifkin RM; Peck SR
    J Oncol Pract; 2017 Sep; 13(9_suppl):24s-31s. PubMed ID: 28898593
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biosimilars: a cure to the U.S. health care cost conundrum?
    Hirsch BR; Lyman GH
    Blood Rev; 2014 Nov; 28(6):263-8. PubMed ID: 25260225
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The constitutional protection of trade secrets and patents under the Biologics Price Competition and Innovation Act of 2009.
    Epstein RA
    Food Drug Law J; 2011; 66(3):285-328. PubMed ID: 24505851
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biosimilars: the need, the challenge, the future: the FDA perspective.
    Epstein MS; Ehrenpreis ED; Kulkarni PM;
    Am J Gastroenterol; 2014 Dec; 109(12):1856-9. PubMed ID: 24957160
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biosimilar safety considerations in clinical practice.
    Choy E; Jacobs IA
    Semin Oncol; 2014 Feb; 41 Suppl 1():S3-14. PubMed ID: 24560025
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biosimilars: impact of differences with Hatch-Waxman.
    Kowalchyk K; Crowley-Weber C
    Pharm Pat Anal; 2013 Jan; 2(1):29-37. PubMed ID: 24236968
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Competition Between Biosimilars and Patented Biologics: Learning from European and Japanese Experience.
    Bocquet F; Loubière A; Fusier I; Cordonnier AL; Paubel P
    Pharmacoeconomics; 2016 Nov; 34(11):1173-1186. PubMed ID: 27412251
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Will biosimilars gain momentum?
    Hirsch BR; Lyman GH
    J Natl Compr Canc Netw; 2013 Oct; 11(10):1291-7. PubMed ID: 24142828
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biosimilars: Exploring the History, Science, and Progress.
    Tariman JD
    Clin J Oncol Nurs; 2018 Oct; 22(5):5-12. PubMed ID: 30239529
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Current market and regulatory landscape of biosimilars.
    Bhatt V
    Am J Manag Care; 2018 Nov; 24(21 Suppl):S451-S456. PubMed ID: 30452213
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Postmarket policy considerations for biosimilar oncology drugs.
    Renwick MJ; Smolina K; Gladstone EJ; Weymann D; Morgan SG
    Lancet Oncol; 2016 Jan; 17(1):e31-8. PubMed ID: 26758759
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Developing oncology biosimilars: an essential approach for the future.
    Abraham J
    Semin Oncol; 2013 Dec; 40 Suppl 1():S5-24. PubMed ID: 24267944
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.